Generics increase competition: study
The study by an MIT professor and Analysis Group researchers reportedly confirmed that the increase in generics had not reduced incentives to challenge brand name patents.
Sandoz counsel argued that Amgen's position "wrongly delays the marketing of every biosimilar."
Some leaders have stepped up, and this serves their companies - and the industry - well.
A study published in Health Affairs detailed an outcomes-based pilot developed by the drugmaker and Priority Health, a Michigan-based health insurer.